Dexamethasone API Marketing Application Approved
March 13, 2026
Source: drugdu
31
March 13th - Cyto BiotechThe announcement stated that the company's controlling subsidiary, Shandong Srui Pharmaceutical Co., Ltd., received a certificate from the National Medical Products Administration for dexamethasone, a chemical raw material."Notification of Approval for Drug Marketing Application". Dexamethasone is a long-acting glucocorticoid with anti-inflammatory, anti-allergic, and immunosuppressive effects. It is mainly used for allergic and autoimmune inflammatory diseases, such as connective tissue diseases, severe bronchial asthma, dermatitis, ulcerative colitis, acute leukemia, and malignant lymphoma.
https://finance.eastmoney.com/a/202603133671477849.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Fangda Pharma helps Jiminke’s Class 1 innovative drug, Jilemei®, obtain market approval. March 13, 2026
- China’s first innovative drug prescription based on precise postoperative assessment for thyroid cancer March 13, 2026
- The launch meeting for the research project on innovative chemical drugs for Alzheimer’s disease was held. March 13, 2026
- Announcement Regarding the Inclusion of its Innovative Drug HSK31679 Tablets in the Breakthrough Therapy Program March 13, 2026
- SHR-9803 for Injection Approved for Clinical Trials March 12, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
